860575P

C8 L-threo-Lactosyl(β) Ceramide (d18:1/8:0)

Avanti Research^™ - A Croda Brand 860575P, powder

• Synonym(e): D-lactosyl-β1-1′-N-octanoyl-L-threo-sphingosine
• Empirische Formel (Hill-System): C₃₈H₇₁NO₁₃
• CAS-Nummer: 939036-94-9
• Molekulargewicht: 749.97
• MDL-Nummer: MFCD28143570
• UNSPSC-Code: 12352211
• NACRES: NA.25

Eigenschaften

• Form: powder
• Verpackung: pkg of 1 × 1 mg (860575P-1mg)
• Hersteller/Markenname: Avanti Research^™ - A Croda Brand 860575P
• Lipid-Typ: sphingolipids
• Versandbedingung: dry ice
• Lagertemp.: −20°C
• SMILES String: CCCCCCCCCCCCC/C=C/[C@@](O)([H])[C@@]([H])(NC(CCCCCCC)=O)CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O[C@H](O2)[C@H](O)[C@@H](O)[C@H]([C@H]2CO)O
• InChIKey: JUCWRRXMPGRQOG-CKTHHAJGSA-N

Beschreibung

Allgemeine Beschreibung

C8 L-threo-Lactosyl(β) Ceramide (d18:1/8:0) is a synthetic glycosphingolipid (GSL) with nonnatural stereochemistry.

Anwendung

C8 L-threo-Lactosyl(β) Ceramide (d18:1/8:0) may be used to disrupt brain-derived neurotropic factor (BDNF)-induced integrin clustering.[1]

Biochem./physiol. Wirkung

C8 L-threo-Lactosyl(β) Ceramide (d18:1/8:0) is a caveolar uptake inhibitor, which blocks SV40 virus infection. It also prevents E1-integrin activation and downstream signaling.[1] C8 L-threo-Lactosyl(β) Ceramide (d18:1/8:0) can deter the aggregation of lipids and proteins into glycosphingolipids (GSLs) and cholesterol-enriched microdomains (rafts) at the plasma membrane (PM).

Verpackung

5 mL Amber Glass Screw Cap Vial (860575P-1mg)

Rechtliche Hinweise

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3